まとめ
ジンとトニックを砂糖と一緒に飲むと,反応性低血糖症になり,神経グリコペニーの症状を引き起こす可能性があります. アルコールによるこの低血糖症は,血中アルコール濃度が低い場合でも,事故のリスクを増やす可能性があります.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 神経科学は神経科学である.
- 毒理学 毒理学 毒理学
背景:
- アルコールの消費は一般的であり,その代謝効果は顕著である.
- アルコール,砂糖,およびグルコースの調節との相互作用は完全に理解されていません.
- 反応性低血糖症は,神経学的症状を引き起こし,パフォーマンスを低下させる可能性があります.
研究 の 目的:
- ジン・アンド・トニックのアルコールと砂糖が血糖とインスリンレベルに及ぼす影響を調査する.
- 異なるジンとトニック製剤を摂取した後の反応性低血糖症および神経グリコペニック症状の発生を評価する.
- アルコールによる低血糖症と機能障害の潜在的な関連性を調査する.
主な方法:
- 10人の健康な若者がコントロールされた研究に参加しました.
- 参加者は,3種類の飲料を飲みました. ジンとトニック (砂糖), ジンと"スリムライン"トニック (低糖), トニック (砂糖) だけで.
- 行動,症状,血糖,血インスリンを摂取後5時間間モニタリングした.
主要な成果:
- 両方のアルコール含有飲料は,軽度から中等度の酔っぱらいを誘発した.
- "スリムライン"トニックを併用したジンは,血糖値やインスリンレベルに有意な影響を及ぼさなかった.
- ジンとトニック (砂糖) はインスリン濃度の上昇と反応性低血糖症を引き起こし,3人の被験者に神経糖質症候群の症状を引き起こしました.
結論:
- ジンとトニックのような飲料の砂糖と組み合わせたアルコールは,反応性低血糖症を引き起こす可能性があります.
- このアルコール誘発反応性低血糖症は,神経グリコペニーの症状を引き起こし,認知機能を低下させる可能性があります.
- この発見は,特に血中アルコール濃度が低下する午後遅く,事故の潜在的なリスク要因を示唆しています.
さらに関連する動画
04:54Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans
Published on: June 2, 2023
03:25Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease
Published on: December 27, 2024
関連する概念動画
SBAR II: Application of SBAR
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
